Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (mNSCLC): Results from CheckMate 227

被引：0
|
作者：
Reck, Martin [1 ]
Brahmer, Julie R. [2 ]
Lee, Jong-Seok [3 ]
Ciuleanu, Tudor-Eliade [4 ,5 ]
Caro, Reyes Bernabe [6 ]
Nishio, Makoto [7 ]
Urban, Laszlo [8 ]
Audigier-Valette, Clarisse [9 ]
Lupinacci, Lorena [10 ]
Sangha, Randeep [11 ]
Paz-Ares, Luis [12 ]
Borghaei, Hossein [13 ]
O'byrne, Kenneth John [14 ,15 ]
Gupta, Ravi G. [16 ]
Bushong, Judith [16 ]
Li, Li [16 ]
Blum, Steven I. [16 ]
Eccles, Laura [16 ]
Ramalingam, Suresh S. [17 ]
机构：
[1] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany
[2] Johns Hopkins Kimmel Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[3] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[4] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[5] Univ Med & Pharm Iulia Hatieganu, Cluj Napoca, Romania
[6] Hosp Univ Virgen Rocio, Inst Biomed Seville, Seville, Spain
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[8] Matrai Gyogyintezet, Matrahaza, Hungary
[9] Hop St Musse, Orientat Oncolog Pole14, Toulon, France
[10] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[11] Cross Canc Inst, Edmonton, AB, Canada
[12] Univ Complutense Madrid, Hosp Univ 12 Octubre, Madrid, Spain
[13] Fox Chase Canc Ctr, Philadelphia, PA USA
[14] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[15] Queensland Univ Technol, Brisbane, Qld, Australia
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
920
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [41] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
    Kato, Ken
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Patel, Apurva
    Hu, Nan
    Matsumura, Yasuhiro
    Chau, Ian
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 290 - 290
  • [42] Nivolumab (N) plus Low-Dose Ipilimumab (I) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Checkmate 227 Part 1 Final Analysis
    Reck, Martin
    Peters, Solange
    Ramalingam, Suresh
    Paz-Ares, Luis
    Bernabe Caro, Reyes
    Zurawski, Bogdan
    Kim, Sang-We
    Alexandru, Aurelia
    Lupinacci, Lorena
    de la Mora Jitnenez, Emmanuel
    Sakai, Hiroshi
    Albert, Istvan
    Vergnenegre, Alain
    Borghaei, Hossein
    Brahmer, Julie R.
    O'byrne, Kenneth
    Geese, William J.
    Bhagavatheeswaran, Prabhu
    Nattan, Faith E.
    Hellmann, Matthew D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 234
  • [43] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
    Chau, I.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C.
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M.
    Holtved, E.
    Murphy, M. Blum
    Abdullaev, S.
    Soleymani, S.
    Lei, M.
    Kato, K.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
  • [44] Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
    Reck, M.
    De, T.
    Paz-Ares, L.
    Yuan, Y.
    Chaudhary, A.
    Lee, A.
    Varol, N.
    Penrod, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1024 - S1024
  • [45] TUMOR GROWTH DYNAMIC (TGD) MODELING AND SAFETY ANALYSIS OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) IN FIRST-LINE (1L) PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC).
    Zhao, X.
    Feng, Y.
    Wang, X.
    Young, T. C.
    Maier, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S53 - S53
  • [46] First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Cobo, Manuel
    Schenker, Michael
    Zurawski, Bogdan
    de Menezes, Juliana Janoski
    Richardet, Eduardo
    Felip, Jaafar Bennouna Enriqueta
    Juan-Vidal, Oscar
    Alexandru, Aurella
    Sakai, Hiroshi
    Scherpereel, Arnaud
    Lu, Shun
    Paz-Ares, Luis G.
    Carbone, David Paul
    Memaj, Arteid
    Marimuthu, Sathiya
    Phuong Tran
    John, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [48] First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
    Kuon, J. B.
    von der Heyde, E.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Forstbauer, H.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2023, 34
  • [49] Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Ramalingam, S. S.
    Balli, D.
    Ciuleanu, T-E.
    Pluzanski, A.
    Lee, J-S.
    Schenker, M.
    Caro, R. Bernabe
    Lee, K. H.
    Bartolucci, R.
    Audigier-Valette, C.
    Hellmann, M. D.
    Paz-Ares, L. G.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K.
    Tran, P.
    Spires, T.
    Geese, W. J.
    Agrawal, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1375 - S1376
  • [50] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
    Adenis, A.
    Chau, I.
    Ajani, J. A.
    Kitagawa, Y.
    Xu, J.
    Wyrwicz, L. S.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C-H.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. I.
    Holtved, E.
    Murphy, M. Blum
    Zhang, J.
    Hu, N.
    Matsumura, Y.
    Kato, K.
    Doki, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S161 - S162
12345